APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Drug Conjugate

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide Drug Conjugate Market Analysis and Forecast 2026-2032

23 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide Drug Conjugate Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Drug Conjugate Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Drug Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Drug Conjugate Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Drug Conjugate Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Peptide Drug Conjugate market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide Drug Conjugate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide Drug Conjugate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide Drug Conjugate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide Drug Conjugate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Peptide Drug Conjugate include Zhongshan Laibo Ruichen Biopharmaceutical, XINOGEN (HONG KONG) PHARMA, Tianjin Conjustar Biotechnology, Lumosa Therapeutics, Shanghai Pharmaceuticals, Shanghai Huiyong Pharmaceutical, Gaorui Yaoye(Beijing)Technologies, BrightGene Bio-Medical Technology and Beijing Shenogen Pharma Group, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide Drug Conjugate, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide Drug Conjugate, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Drug Conjugate, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Drug Conjugate sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide Drug Conjugate market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peptide Drug Conjugate sales, projected growth trends, production technology, application and end-user industry.

Peptide Drug Conjugate Segment by Company

Zhongshan Laibo Ruichen Biopharmaceutical

XINOGEN (HONG KONG) PHARMA

Tianjin Conjustar Biotechnology

Lumosa Therapeutics

Shanghai Pharmaceuticals

Shanghai Huiyong Pharmaceutical

Gaorui Yaoye(Beijing)Technologies

BrightGene Bio-Medical Technology

Beijing Shenogen Pharma Group

Theratechnologies

Cybrexa Therapeutics

Bicycle Therapeutics

Peptide Drug Conjugate Segment by Type

Cell Targeting Peptides (CTP)

Cell-penetrating Peptides (CPP)

Others

Peptide Drug Conjugate Segment by Application

Breast Cancer

Pancreatic Cancer

Others

Peptide Drug Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Drug Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Drug Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Drug Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide Drug Conjugate in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide Drug Conjugate manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Drug Conjugate sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide Drug Conjugate Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cell Targeting Peptides (CTP) Major Manufacturers Table 3. Cell-penetrating Peptides (CPP) Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Peptide Drug Conjugate Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Breast Cancer Major Manufacturers Table 7. Pancreatic Cancer Major Manufacturers Table 8. Others Major Manufacturers Table 9. Peptide Drug Conjugate Industry Trends Table 10. Peptide Drug Conjugate Industry Drivers Table 11. Peptide Drug Conjugate Industry Opportunities and Challenges Table 12. Peptide Drug Conjugate Industry Restraints Table 13. Global Peptide Drug Conjugate Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Peptide Drug Conjugate Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Peptide Drug Conjugate Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Peptide Drug Conjugate Revenue Market Share by Region (2021-2026) Table 17. Global Peptide Drug Conjugate Revenue Market Share by Region (2027-2032) Table 18. Global Peptide Drug Conjugate Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Peptide Drug Conjugate Sales by Region (2021-2026) & (k units) Table 20. Global Peptide Drug Conjugate Sales by Region (2027-2032) & (k units) Table 21. Global Peptide Drug Conjugate Sales Market Share by Region (2021-2026) Table 22. Global Peptide Drug Conjugate Sales Market Share by Region (2027-2032) Table 23. Global Peptide Drug Conjugate Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Peptide Drug Conjugate Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Peptide Drug Conjugate Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Peptide Drug Conjugate Sales Market Share by Manufacturers (2021-2026) Table 27. Global Peptide Drug Conjugate Sales Price (USD/unit) of Manufacturers (2021-2026) Table 28. Global Peptide Drug Conjugate Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Peptide Drug Conjugate Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Peptide Drug Conjugate Manufacturers, Product Type & Application Table 31. Global Peptide Drug Conjugate Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Peptide Drug Conjugate by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Peptide Drug Conjugate Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2026) Table 38. Global Peptide Drug Conjugate Revenue Market Share by Type (2027-2032) Table 39. Global Peptide Drug Conjugate Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 41. Global Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 42. Global Peptide Drug Conjugate Sales Market Share by Type (2021-2026) Table 43. Global Peptide Drug Conjugate Sales Market Share by Type (2027-2032) Table 44. Global Peptide Drug Conjugate Price by Type (2021-2026) & (USD/unit) Table 45. Global Peptide Drug Conjugate Price by Type (2027-2032) & (USD/unit) Table 46. Global Peptide Drug Conjugate Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2026) Table 50. Global Peptide Drug Conjugate Revenue Market Share by Application (2027-2032) Table 51. Global Peptide Drug Conjugate Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 53. Global Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 54. Global Peptide Drug Conjugate Sales Market Share by Application (2021-2026) Table 55. Global Peptide Drug Conjugate Sales Market Share by Application (2027-2032) Table 56. Global Peptide Drug Conjugate Price by Application (2021-2026) & (USD/unit) Table 57. Global Peptide Drug Conjugate Price by Application (2027-2032) & (USD/unit) Table 58. Zhongshan Laibo Ruichen Biopharmaceutical Company Information Table 59. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview Table 60. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio Table 62. Zhongshan Laibo Ruichen Biopharmaceutical Recent Development Table 63. XINOGEN (HONG KONG) PHARMA Company Information Table 64. XINOGEN (HONG KONG) PHARMA Business Overview Table 65. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio Table 67. XINOGEN (HONG KONG) PHARMA Recent Development Table 68. Tianjin Conjustar Biotechnology Company Information Table 69. Tianjin Conjustar Biotechnology Business Overview Table 70. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio Table 72. Tianjin Conjustar Biotechnology Recent Development Table 73. Lumosa Therapeutics Company Information Table 74. Lumosa Therapeutics Business Overview Table 75. Lumosa Therapeutics Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio Table 77. Lumosa Therapeutics Recent Development Table 78. Shanghai Pharmaceuticals Company Information Table 79. Shanghai Pharmaceuticals Business Overview Table 80. Shanghai Pharmaceuticals Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio Table 82. Shanghai Pharmaceuticals Recent Development Table 83. Shanghai Huiyong Pharmaceutical Company Information Table 84. Shanghai Huiyong Pharmaceutical Business Overview Table 85. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio Table 87. Shanghai Huiyong Pharmaceutical Recent Development Table 88. Gaorui Yaoye(Beijing)Technologies Company Information Table 89. Gaorui Yaoye(Beijing)Technologies Business Overview Table 90. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio Table 92. Gaorui Yaoye(Beijing)Technologies Recent Development Table 93. BrightGene Bio-Medical Technology Company Information Table 94. BrightGene Bio-Medical Technology Business Overview Table 95. BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio Table 97. BrightGene Bio-Medical Technology Recent Development Table 98. Beijing Shenogen Pharma Group Company Information Table 99. Beijing Shenogen Pharma Group Business Overview Table 100. Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio Table 102. Beijing Shenogen Pharma Group Recent Development Table 103. Theratechnologies Company Information Table 104. Theratechnologies Business Overview Table 105. Theratechnologies Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Theratechnologies Peptide Drug Conjugate Product Portfolio Table 107. Theratechnologies Recent Development Table 108. Cybrexa Therapeutics Company Information Table 109. Cybrexa Therapeutics Business Overview Table 110. Cybrexa Therapeutics Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio Table 112. Cybrexa Therapeutics Recent Development Table 113. Bicycle Therapeutics Company Information Table 114. Bicycle Therapeutics Business Overview Table 115. Bicycle Therapeutics Peptide Drug Conjugate Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio Table 117. Bicycle Therapeutics Recent Development Table 118. North America Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 119. North America Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 120. North America Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 121. North America Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 122. North America Peptide Drug Conjugate Sales Price by Type (2021-2026) & (USD/unit) Table 123. North America Peptide Drug Conjugate Sales Price by Type (2027-2032) & (USD/unit) Table 124. North America Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 127. North America Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 128. North America Peptide Drug Conjugate Sales Price by Application (2021-2026) & (USD/unit) Table 129. North America Peptide Drug Conjugate Sales Price by Application (2027-2032) & (USD/unit) Table 130. North America Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Peptide Drug Conjugate Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. North America Peptide Drug Conjugate Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. North America Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 134. North America Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 135. North America Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 136. North America Peptide Drug Conjugate Sales Price by Country (2021-2026) & (USD/unit) Table 137. North America Peptide Drug Conjugate Sales Price by Country (2027-2032) & (USD/unit) Table 138. United States Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 139. Canada Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 140. Mexico Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 141. Europe Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 142. Europe Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 143. Europe Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 144. Europe Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 145. Europe Peptide Drug Conjugate Sales Price by Type (2021-2026) & (USD/unit) Table 146. Europe Peptide Drug Conjugate Sales Price by Type (2027-2032) & (USD/unit) Table 147. Europe Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 150. Europe Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 151. Europe Peptide Drug Conjugate Sales Price by Application (2021-2026) & (USD/unit) Table 152. Europe Peptide Drug Conjugate Sales Price by Application (2027-2032) & (USD/unit) Table 153. Europe Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Europe Peptide Drug Conjugate Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 155. Europe Peptide Drug Conjugate Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 156. Europe Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 157. Europe Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 158. Europe Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 159. Europe Peptide Drug Conjugate Sales Price by Country (2021-2026) & (USD/unit) Table 160. Europe Peptide Drug Conjugate Sales Price by Country (2027-2032) & (USD/unit) Table 161. Germany Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 162. France Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 163. U.K. Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 164. Italy Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 165. Russia Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 166. Spain Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 167. Netherlands Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 168. Switzerland Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 169. Sweden Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 170. Poland Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 171. China Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 172. China Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 173. China Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 174. China Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 175. China Peptide Drug Conjugate Sales Price by Type (2021-2026) & (USD/unit) Table 176. China Peptide Drug Conjugate Sales Price by Type (2027-2032) & (USD/unit) Table 177. China Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 178. China Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 179. China Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 180. China Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 181. China Peptide Drug Conjugate Sales Price by Application (2021-2026) & (USD/unit) Table 182. China Peptide Drug Conjugate Sales Price by Application (2027-2032) & (USD/unit) Table 183. Asia Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 184. Asia Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 185. Asia Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 186. Asia Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 187. Asia Peptide Drug Conjugate Sales Price by Type (2021-2026) & (USD/unit) Table 188. Asia Peptide Drug Conjugate Sales Price by Type (2027-2032) & (USD/unit) Table 189. Asia Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 190. Asia Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 191. Asia Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 192. Asia Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 193. Asia Peptide Drug Conjugate Sales Price by Application (2021-2026) & (USD/unit) Table 194. Asia Peptide Drug Conjugate Sales Price by Application (2027-2032) & (USD/unit) Table 195. Asia Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. Asia Peptide Drug Conjugate Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 197. Asia Peptide Drug Conjugate Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 198. Asia Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 199. Asia Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 200. Asia Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 201. Asia Peptide Drug Conjugate Sales Price by Country (2021-2026) & (USD/unit) Table 202. Asia Peptide Drug Conjugate Sales Price by Country (2027-2032) & (USD/unit) Table 203. Japan Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 204. South Korea Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 205. India Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 206. Australia Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 207. Taiwan Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 208. Southeast Asia Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 209. SAMEA Peptide Drug Conjugate Revenue by Type (2021-2026) & (US$ Million) Table 210. SAMEA Peptide Drug Conjugate Revenue by Type (2027-2032) & (US$ Million) Table 211. SAMEA Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 212. SAMEA Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 213. SAMEA Peptide Drug Conjugate Sales Price by Type (2021-2026) & (USD/unit) Table 214. SAMEA Peptide Drug Conjugate Sales Price by Type (2027-2032) & (USD/unit) Table 215. SAMEA Peptide Drug Conjugate Revenue by Application (2021-2026) & (US$ Million) Table 216. SAMEA Peptide Drug Conjugate Revenue by Application (2027-2032) & (US$ Million) Table 217. SAMEA Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 218. SAMEA Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 219. SAMEA Peptide Drug Conjugate Sales Price by Application (2021-2026) & (USD/unit) Table 220. SAMEA Peptide Drug Conjugate Sales Price by Application (2027-2032) & (USD/unit) Table 221. SAMEA Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. SAMEA Peptide Drug Conjugate Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. SAMEA Peptide Drug Conjugate Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. SAMEA Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 225. SAMEA Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 226. SAMEA Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 227. SAMEA Peptide Drug Conjugate Sales Price by Country (2021-2026) & (USD/unit) Table 228. SAMEA Peptide Drug Conjugate Sales Price by Country (2027-2032) & (USD/unit) Table 229. Brazil Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 230. Argentina Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 231. Chile Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 232. Colombia Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 233. Peru Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 234. Saudi Arabia Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 235. Israel Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 236. UAE Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 237. Turkey Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 238. Iran Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 239. Egypt Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Table 240. Key Raw Materials Table 241. Raw Materials Key Suppliers Table 242. Peptide Drug Conjugate Distributors List Table 243. Peptide Drug Conjugate Customers List Table 244. Research Programs/Design for This Report Table 245. Authors List of This Report Table 246. Secondary Sources Table 247. Primary Sources List of Figures Figure 1. Peptide Drug Conjugate Image Figure 2. Global Peptide Drug Conjugate Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Drug Conjugate Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cell Targeting Peptides (CTP) Image Figure 5. Cell-penetrating Peptides (CPP) Image Figure 6. Others Image Figure 7. Global Peptide Drug Conjugate Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Peptide Drug Conjugate Market Size Share 2021 VS 2025 VS 2032 Figure 9. Breast Cancer Image Figure 10. Pancreatic Cancer Image Figure 11. Others Image Figure 12. Global Peptide Drug Conjugate Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Figure 14. Global Peptide Drug Conjugate Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Peptide Drug Conjugate Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Peptide Drug Conjugate Revenue Market Share by Region (2021-2032) Figure 17. Global Peptide Drug Conjugate Sales (2021-2032) & (k units) Figure 18. Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Peptide Drug Conjugate Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Peptide Drug Conjugate Sales YoY (2021-2032) & (k units) Figure 21. Europe Peptide Drug Conjugate Sales YoY (2021-2032) & (k units) Figure 22. China Peptide Drug Conjugate Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Peptide Drug Conjugate Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Peptide Drug Conjugate Sales YoY (2021-2032) & (k units) Figure 25. Global Peptide Drug Conjugate Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Peptide Drug Conjugate Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Peptide Drug Conjugate Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Peptide Drug Conjugate Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2032) Figure 31. Global Peptide Drug Conjugate Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Peptide Drug Conjugate Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Peptide Drug Conjugate Sales Market Share by Type (2021-2032) Figure 34. Global Peptide Drug Conjugate Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Peptide Drug Conjugate Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2032) Figure 37. Global Peptide Drug Conjugate Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Peptide Drug Conjugate Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Peptide Drug Conjugate Sales Market Share by Application (2021-2032) Figure 40. North America Peptide Drug Conjugate Revenue Share by Type (2021-2032) Figure 41. North America Peptide Drug Conjugate Sales Share by Type (2021-2032) Figure 42. North America Peptide Drug Conjugate Revenue Share by Application (2021-2032) Figure 43. North America Peptide Drug Conjugate Sales Share by Application (2021-2032) Figure 44. North America Peptide Drug Conjugate Revenue Share by Country (2021-2032) Figure 45. North America Peptide Drug Conjugate Sales Share by Country (2021-2032) Figure 46. Europe Peptide Drug Conjugate Revenue Share by Type (2021-2032) Figure 47. Europe Peptide Drug Conjugate Sales Share by Type (2021-2032) Figure 48. Europe Peptide Drug Conjugate Revenue Share by Application (2021-2032) Figure 49. Europe Peptide Drug Conjugate Sales Share by Application (2021-2032) Figure 50. Europe Peptide Drug Conjugate Revenue Share by Country (2021-2032) Figure 51. Europe Peptide Drug Conjugate Sales Share by Country (2021-2032) Figure 52. China Peptide Drug Conjugate Revenue Share by Type (2021-2032) Figure 53. China Peptide Drug Conjugate Sales Share by Type (2021-2032) Figure 54. China Peptide Drug Conjugate Revenue Share by Application (2021-2032) Figure 55. China Peptide Drug Conjugate Sales Share by Application (2021-2032) Figure 56. Asia Peptide Drug Conjugate Revenue Share by Type (2021-2032) Figure 57. Asia Peptide Drug Conjugate Sales Share by Type (2021-2032) Figure 58. Asia Peptide Drug Conjugate Revenue Share by Application (2021-2032) Figure 59. Asia Peptide Drug Conjugate Sales Share by Application (2021-2032) Figure 60. Asia Peptide Drug Conjugate Revenue Share by Country (2021-2032) Figure 61. Asia Peptide Drug Conjugate Sales Share by Country (2021-2032) Figure 62. SAMEA Peptide Drug Conjugate Revenue Share by Type (2021-2032) Figure 63. SAMEA Peptide Drug Conjugate Sales Share by Type (2021-2032) Figure 64. SAMEA Peptide Drug Conjugate Revenue Share by Application (2021-2032) Figure 65. SAMEA Peptide Drug Conjugate Sales Share by Application (2021-2032) Figure 66. SAMEA Peptide Drug Conjugate Revenue Share by Country (2021-2032) Figure 67. SAMEA Peptide Drug Conjugate Sales Share by Country (2021-2032) Figure 68. Peptide Drug Conjugate Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Peptide Drug Conjugate Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Targeting Peptides (CTP)
  • Cell-penetrating Peptides (CPP)
  • Others
Applications
  • Breast Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Zhongshan Laibo Ruichen Biopharmaceutical
  • XINOGEN (HONG KONG) PHARMA
  • Tianjin Conjustar Biotechnology
  • Lumosa Therapeutics
  • Shanghai Pharmaceuticals
  • Shanghai Huiyong Pharmaceutical
  • Gaorui Yaoye(Beijing)Technologies
  • BrightGene Bio-Medical Technology
  • Beijing Shenogen Pharma Group
  • Theratechnologies
  • Cybrexa Therapeutics
  • Bicycle Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide Drug Conjugate Market by Type
  3. 1.2.1 Global Peptide Drug Conjugate Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cell Targeting Peptides (CTP)
  5. 1.2.3 Cell-penetrating Peptides (CPP)
  6. 1.2.4 Others
  7. 1.3 Peptide Drug Conjugate Market by Application
  8. 1.3.1 Global Peptide Drug Conjugate Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Breast Cancer
  10. 1.3.3 Pancreatic Cancer
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Peptide Drug Conjugate Market Dynamics
  1. 2.1 Peptide Drug Conjugate Industry Trends
  2. 2.2 Peptide Drug Conjugate Industry Drivers
  3. 2.3 Peptide Drug Conjugate Industry Opportunities and Challenges
  4. 2.4 Peptide Drug Conjugate Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peptide Drug Conjugate Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peptide Drug Conjugate Revenue by Region
  3. 3.2.1 Global Peptide Drug Conjugate Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide Drug Conjugate Revenue by Region (2021-2026)
  5. 3.2.3 Global Peptide Drug Conjugate Revenue by Region (2027-2032)
  6. 3.2.4 Global Peptide Drug Conjugate Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peptide Drug Conjugate Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peptide Drug Conjugate Sales by Region
  9. 3.4.1 Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peptide Drug Conjugate Sales by Region (2021-2026)
  11. 3.4.3 Global Peptide Drug Conjugate Sales by Region (2027-2032)
  12. 3.4.4 Global Peptide Drug Conjugate Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peptide Drug Conjugate Revenue by Manufacturers
  2. 4.1.1 Global Peptide Drug Conjugate Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peptide Drug Conjugate Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peptide Drug Conjugate Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide Drug Conjugate Sales by Manufacturers
  6. 4.2.1 Global Peptide Drug Conjugate Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peptide Drug Conjugate Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peptide Drug Conjugate Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peptide Drug Conjugate Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peptide Drug Conjugate Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peptide Drug Conjugate Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peptide Drug Conjugate Manufacturers, Product Type & Application
  13. 4.7 Global Peptide Drug Conjugate Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peptide Drug Conjugate Market CR5 and HHI
  16. 4.8.2 2025 Peptide Drug Conjugate Tier 1, Tier 2, and Tier 3
5 Peptide Drug Conjugate Market by Type
  1. 5.1 Global Peptide Drug Conjugate Revenue by Type
  2. 5.1.1 Global Peptide Drug Conjugate Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peptide Drug Conjugate Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peptide Drug Conjugate Sales by Type
  6. 5.2.1 Global Peptide Drug Conjugate Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Drug Conjugate Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Peptide Drug Conjugate Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peptide Drug Conjugate Price by Type
6 Peptide Drug Conjugate Market by Application
  1. 6.1 Global Peptide Drug Conjugate Revenue by Application
  2. 6.1.1 Global Peptide Drug Conjugate Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peptide Drug Conjugate Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peptide Drug Conjugate Sales by Application
  6. 6.2.1 Global Peptide Drug Conjugate Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peptide Drug Conjugate Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Peptide Drug Conjugate Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peptide Drug Conjugate Price by Application
7 Company Profiles
  1. 7.1 Zhongshan Laibo Ruichen Biopharmaceutical
  2. 7.1.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
  3. 7.1.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
  4. 7.1.3 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio
  6. 7.1.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
  7. 7.2 XINOGEN (HONG KONG) PHARMA
  8. 7.2.1 XINOGEN (HONG KONG) PHARMA Company Information
  9. 7.2.2 XINOGEN (HONG KONG) PHARMA Business Overview
  10. 7.2.3 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio
  12. 7.2.5 XINOGEN (HONG KONG) PHARMA Recent Developments
  13. 7.3 Tianjin Conjustar Biotechnology
  14. 7.3.1 Tianjin Conjustar Biotechnology Company Information
  15. 7.3.2 Tianjin Conjustar Biotechnology Business Overview
  16. 7.3.3 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio
  18. 7.3.5 Tianjin Conjustar Biotechnology Recent Developments
  19. 7.4 Lumosa Therapeutics
  20. 7.4.1 Lumosa Therapeutics Company Information
  21. 7.4.2 Lumosa Therapeutics Business Overview
  22. 7.4.3 Lumosa Therapeutics Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio
  24. 7.4.5 Lumosa Therapeutics Recent Developments
  25. 7.5 Shanghai Pharmaceuticals
  26. 7.5.1 Shanghai Pharmaceuticals Company Information
  27. 7.5.2 Shanghai Pharmaceuticals Business Overview
  28. 7.5.3 Shanghai Pharmaceuticals Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio
  30. 7.5.5 Shanghai Pharmaceuticals Recent Developments
  31. 7.6 Shanghai Huiyong Pharmaceutical
  32. 7.6.1 Shanghai Huiyong Pharmaceutical Company Information
  33. 7.6.2 Shanghai Huiyong Pharmaceutical Business Overview
  34. 7.6.3 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio
  36. 7.6.5 Shanghai Huiyong Pharmaceutical Recent Developments
  37. 7.7 Gaorui Yaoye(Beijing)Technologies
  38. 7.7.1 Gaorui Yaoye(Beijing)Technologies Company Information
  39. 7.7.2 Gaorui Yaoye(Beijing)Technologies Business Overview
  40. 7.7.3 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio
  42. 7.7.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
  43. 7.8 BrightGene Bio-Medical Technology
  44. 7.8.1 BrightGene Bio-Medical Technology Company Information
  45. 7.8.2 BrightGene Bio-Medical Technology Business Overview
  46. 7.8.3 BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio
  48. 7.8.5 BrightGene Bio-Medical Technology Recent Developments
  49. 7.9 Beijing Shenogen Pharma Group
  50. 7.9.1 Beijing Shenogen Pharma Group Company Information
  51. 7.9.2 Beijing Shenogen Pharma Group Business Overview
  52. 7.9.3 Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio
  54. 7.9.5 Beijing Shenogen Pharma Group Recent Developments
  55. 7.10 Theratechnologies
  56. 7.10.1 Theratechnologies Company Information
  57. 7.10.2 Theratechnologies Business Overview
  58. 7.10.3 Theratechnologies Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Theratechnologies Peptide Drug Conjugate Product Portfolio
  60. 7.10.5 Theratechnologies Recent Developments
  61. 7.11 Cybrexa Therapeutics
  62. 7.11.1 Cybrexa Therapeutics Company Information
  63. 7.11.2 Cybrexa Therapeutics Business Overview
  64. 7.11.3 Cybrexa Therapeutics Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio
  66. 7.11.5 Cybrexa Therapeutics Recent Developments
  67. 7.12 Bicycle Therapeutics
  68. 7.12.1 Bicycle Therapeutics Company Information
  69. 7.12.2 Bicycle Therapeutics Business Overview
  70. 7.12.3 Bicycle Therapeutics Peptide Drug Conjugate Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio
  72. 7.12.5 Bicycle Therapeutics Recent Developments
8 North America
  1. 8.1 North America Peptide Drug Conjugate Market Size by Type
  2. 8.1.1 North America Peptide Drug Conjugate Revenue by Type (2021-2032)
  3. 8.1.2 North America Peptide Drug Conjugate Sales by Type (2021-2032)
  4. 8.1.3 North America Peptide Drug Conjugate Price by Type (2021-2032)
  5. 8.2 North America Peptide Drug Conjugate Market Size by Application
  6. 8.2.1 North America Peptide Drug Conjugate Revenue by Application (2021-2032)
  7. 8.2.2 North America Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 8.2.3 North America Peptide Drug Conjugate Price by Application (2021-2032)
  9. 8.3 North America Peptide Drug Conjugate Market Size by Country
  10. 8.3.1 North America Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peptide Drug Conjugate Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Peptide Drug Conjugate Market Size by Type
  2. 9.1.1 Europe Peptide Drug Conjugate Revenue by Type (2021-2032)
  3. 9.1.2 Europe Peptide Drug Conjugate Sales by Type (2021-2032)
  4. 9.1.3 Europe Peptide Drug Conjugate Price by Type (2021-2032)
  5. 9.2 Europe Peptide Drug Conjugate Market Size by Application
  6. 9.2.1 Europe Peptide Drug Conjugate Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 9.2.3 Europe Peptide Drug Conjugate Price by Application (2021-2032)
  9. 9.3 Europe Peptide Drug Conjugate Market Size by Country
  10. 9.3.1 Europe Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peptide Drug Conjugate Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Peptide Drug Conjugate Market Size by Type
  2. 10.1.1 China Peptide Drug Conjugate Revenue by Type (2021-2032)
  3. 10.1.2 China Peptide Drug Conjugate Sales by Type (2021-2032)
  4. 10.1.3 China Peptide Drug Conjugate Price by Type (2021-2032)
  5. 10.2 China Peptide Drug Conjugate Market Size by Application
  6. 10.2.1 China Peptide Drug Conjugate Revenue by Application (2021-2032)
  7. 10.2.2 China Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 10.2.3 China Peptide Drug Conjugate Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide Drug Conjugate Market Size by Type
  2. 11.1.1 Asia Peptide Drug Conjugate Revenue by Type (2021-2032)
  3. 11.1.2 Asia Peptide Drug Conjugate Sales by Type (2021-2032)
  4. 11.1.3 Asia Peptide Drug Conjugate Price by Type (2021-2032)
  5. 11.2 Asia Peptide Drug Conjugate Market Size by Application
  6. 11.2.1 Asia Peptide Drug Conjugate Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 11.2.3 Asia Peptide Drug Conjugate Price by Application (2021-2032)
  9. 11.3 Asia Peptide Drug Conjugate Market Size by Country
  10. 11.3.1 Asia Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peptide Drug Conjugate Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide Drug Conjugate Market Size by Type
  2. 12.1.1 SAMEA Peptide Drug Conjugate Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Peptide Drug Conjugate Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Peptide Drug Conjugate Price by Type (2021-2032)
  5. 12.2 SAMEA Peptide Drug Conjugate Market Size by Application
  6. 12.2.1 SAMEA Peptide Drug Conjugate Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peptide Drug Conjugate Price by Application (2021-2032)
  9. 12.3 SAMEA Peptide Drug Conjugate Market Size by Country
  10. 12.3.1 SAMEA Peptide Drug Conjugate Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peptide Drug Conjugate Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peptide Drug Conjugate Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peptide Drug Conjugate Value Chain Analysis
  2. 13.1.1 Peptide Drug Conjugate Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peptide Drug Conjugate Production Mode & Process
  6. 13.2 Peptide Drug Conjugate Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peptide Drug Conjugate Distributors
  9. 13.2.3 Peptide Drug Conjugate Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst